Inventor · disambiguated record
Tetsuya Nakatsura
Also filed as: NAKATSURA TETSUYA
11 granted patents·8 pending applications·14 citations·filing 2003–2023
84Inventor score
Files withNAT CANCER CT3UNIV YAMAGUCHI3KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION2NAKATSURA TETSUYA2NAT CANCER CENTER JAPAN2
Top patents by PatentIndex Score
19 records- 0186US10781249B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2019·Granted Sep 22, 2020·2 cites·8 claims
- 0282US12129291B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2023·Granted Oct 29, 2024·0 cites·15 claims
- 0381US8053556B2Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the sameONCOTHERAPY SCIENCE INC·Filed 2006·Granted Nov 8, 2011·5 cites·5 claims
- 0466US9404925B2Cancer antigen and use thereofNAKATSURA TETSUYA·Filed 2008·Granted Aug 2, 2016·1 cites·3 claims
- 0566US2023257708A1Novel t-cell receptorNAT CANCER CENTER JAPAN·Filed 2023·Application pending·0 cites
- 0665US2025339504A1Cancer vaccine with use of common cancer antigen cocktail, tcr/car-t cell therapeutic, companion diagnostic method, and method for diagnosing risk of cancer onset by detecting circulating tumor cellsNAT CANCER CT·Filed 2023·Application pending·0 cites
- 0764US8017345B2Diagnostic kit for malignant melanomaUNIV KUMAMOTO·Filed 2005·Granted Sep 13, 2011·2 cites·5 claims
- 0863US11718663B2Anti-GPC3 antibodyUNIV YAMAGUCHI·Filed 2018·Granted Aug 8, 2023·0 cites·18 claims
- 0963US2024016935A1Genetically modified cell and method for producing samePHC CORP·Filed 2023·Application pending·0 cites
- 1058US11603519B2T-cell receptorNAT CANCER CENTER JAPAN·Filed 2018·Granted Mar 14, 2023·0 cites·17 claims
- 1158US9505824B2Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutationKANAGAWA PREFECTURAL HOSPITAL ORGANIZATION·Filed 2013·Granted Nov 29, 2016·2 cites·10 claims
- 1256US7803533B2Diagnostic agent for malignant melanomaKUMAMOTO TECH & IND FOUND·Filed 2004·Granted Sep 28, 2010·2 cites·4 claims
- 1351US8535942B2Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the sameNISHIMURA YASUHARU·Filed 2011·Granted Sep 17, 2013·0 cites·3 claims
- 1446US9465030B2Kit for diagnosing malignant melanomaNAT CANCER CT·Filed 2013·Granted Oct 11, 2016·0 cites·5 claims
- 1543US2006251666A1Cancer antigens and utilization thereofNAKATSURA TETSUYA·Filed 2003·Application pending·0 cites
- 1642US2013045500A1Cell evaluation methodNAT CANCER CT·Filed 2011·Application pending·0 cites
- 1740US2019350979A1Undifferentiated stem cell removal agent and method for removing undifferentiated stem cellsHEARTSEED INC·Filed 2017·Application pending·0 cites
- 1839US2019066846A1Method, apparatus, computer program product and kit for assisting recurrence risk prediction for hepatocellular carcinoma patientsSYSMEX CORP·Filed 2018·Application pending·0 cites
- 1928US2017049870A1Antigen Peptide Derived From the Sequence of Epidermal Growth Factor Receptor Having T790M Point MutationKANAGAWA PREFECTURAL HOSPITAL ORGANIZATION·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tetsuya Nakatsura files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →